Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment

Journal for ImmunoTherapy of Cancer

Volumn 5, Issue 1, 2017, Pages

  Anderson, Erik S ^a   Postow, Michael A ^a   Wolchok, Jedd D ^a   Young, Robert J ^a   Ballangrud, Åse ^a   Chan, Timothy A ^a   Yamada, Yoshiya ^a   Beal, Kathryn ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IPILIMUMAB; PEMBROLIZUMAB; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR;

ADULT; AGED; ARTICLE; BRAIN DAMAGE; BRAIN HEMORRHAGE; BRAIN METASTASIS; CANCER RECURRENCE; CANCER REGRESSION; CLINICAL ARTICLE; COGNITIVE DEFECT; CONFUSION; CONTROLLED STUDY; DATA BASE; DIARRHEA; EDEMA; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPOFRACTIONATED RADIOTHERAPY; IMMUNOTHERAPY; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MELANOMA; NAUSEA; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PRIORITY JOURNAL; PRURITUS; SAFETY; SEIZURE; STEREOTACTIC RADIOSURGERY; TREATMENT RESPONSE; VERY ELDERLY; BRAIN TUMOR; METASTASIS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROCEDURES; RADIOSURGERY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROGRAMMED CELL DEATH 1 RECEPTOR; RADIOSURGERY;

EID: 85031505743     PISSN: None     EISSN: 20511426     Source Type: Journal    
DOI: 10.1186/s40425-017-0282-x     Document Type: Article

References (31)

1. Samlowski WE, et al. Multimodality treatment of melanoma brain metastases incorporating stereotactic radiosurgery (SRS). Cancer. 2007;109:1855-62.
2. Knisely JPS, et al. Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival: clinical article. J Neurosurg. 2012;117:227-33.
3. Sperduto PW, et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol. 2012;30:419-25.
4. Kiess AP, et al. Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. Int J Radiat Oncol Biol Phys. 2015;92:368-75.
5. Schoenfeld JD, et al. Ipilmumab and cranial radiation in metastatic melanoma patients: a case series and review. J Immunother Cancer. 2015;3:50.
6. Patel KR, et al. Ipilimumab and stereotactic Radiosurgery versus stereotactic Radiosurgery alone for newly diagnosed melanoma brain metastases. Am J Clin Oncol. 2015; doi: 10.1097/COC.0000000000000199.
7. Tazi K, Hathaway A, Chiuzan C, Shirai K. Survival of melanoma patients with brain metastases treated with ipilimumab and stereotactic radiosurgery. Cancer Med. 2015;4:1-6.
8. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252-64.
9. Blank C, et al. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res. 2004;64:1140-5.
10. Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol. 2007;19:813-24.
11. Taube JM, et al. Association of PD-1, PD-1 Ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20:5064-74.
12. Brahmer JR, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28:3167-75.
13. Topalian SL, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443-54.
14. Rosenberg JE, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387:1909-20.
15. Le DT, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509-20.
16. Armand P, et al. Programmed Death-1 blockade with Pembrolizumab in patients with classical Hodgkin lymphoma after Brentuximab Vedotin failure. J Clin Oncol Off J Am Soc Clin Oncol. 2016; doi: 10.1200/JCO.2016.67.3467.
17. Ferris RL, et al. Nivolumab for recurrent Squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375:1856-67.
18. Ahmed KA, et al. Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy. Ann Oncol Off J Eur Soc Med Oncol. 2016;27:2288-94.
19. Ahmed KA, et al. Outcomes targeting the PD-1/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases. J Neuro-Oncol. 2017;133:331-8.
20. Liniker E, et al. Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma. Oncoimmunology. 2016;5:e1214788.
21. Robert C, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015;372:2521-32.
22. Goldberg SB, et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2016;17:976-83.
23. Lin NU, et al. Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol. 2015;16:e270-8.
24. Ribas A, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16:908-18.
25. Gieger M, et al. Response of intracranial melanoma metastases to stereotactic radiosurgery. Radiat Oncol Investig. 1997;5:72-80.
26. Yaeh A, et al. Control of brain metastases from radioresistant tumors treated by stereotactic radiosurgery. J Neuro-Oncol. 2015;124:507-14.
27. Linskey ME, et al. The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neuro-Oncol. 2010;96:45-68.
28. Cohen JV, et al. Melanoma Brain Metastasis Pseudoprogression after Pembrolizumab Treatment. Cancer Immunol Res. 2016;4:179-82.
29. Chandra RA, et al. A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab. Oncoimmunology. 2015;4:e1046028.
30. Reardon DA, Okada H. Re-defining response and treatment effects for neuro-oncology immunotherapy clinical trials. J Neuro-Oncol. 2015;123:339-46.
31. Okada H, et al. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 2015;16:e534-42.